...
首页> 外文期刊>Annals of Surgery >Predictive value of microRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study
【24h】

Predictive value of microRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study

机译:在长期随访研究中,microRNA对Barrett食管向腺癌进展的预测价值

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The aim of this study is to identify a set of microRNAs (miRNAs) as prognostic molecular biomarkers for the progression of Barrett esophagus (BE) to esophageal adenocarcinoma (EAC) to rationalize the surveillance programs in patients with BE. BACKGROUND: Histological dysplasia is currently used as the main biomarker to identify the BE patients at high risk for developing EAC. Although miRNA expression profiles in BE and EAC have been reported, it has not been established which set of miRNAs could constitute a robust diagnostic test to predict the progression of BE to EAC. METHODS: miRNAs associated with progression of BE to EAC were identified using miRNA sequencing analysis. Further validation by quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed in 2 groups of BE patients who either developed or did not develop adenocarcinoma after at least 5 years of follow-up. RESULTS: Twenty-three miRNAs were identified by miRNA sequencing analysis in the carcinogenesis process associated with BE. qRT-PCR analysis using independent tissue samples confirmed differential expression for 19 of them (miR-let-7c, 7, 146a, 149, 153, 192, 192*, 194, 194*, 196a, 196b, 200a, 203, 205, 215, 424, 625, 625*, and 944). However, only miR-192, 194, 196a, and 196b showed a significantly higher expression in BE samples from patients with progression to EAC compared with those who did not progress to EAC. CONCLUSIONS: These findings suggest that the expression pattern of a modest number of miRNAs in metaplasia biopsies could identify the BE patients at high risk for developing EAC. Therefore, it has potential use for the control and treatment of this malignancy.
机译:目的:本研究的目的是鉴定一组微RNA(miRNA)作为Barrett食管(BE)演变为食道腺癌(EAC)的预后分子生物标记,以合理化BE患者的监测程序。背景:组织学异常增生目前被用作主要生物标志物,以鉴别出发生EAC的高风险BE患者。尽管已经报道了BE和EAC中的miRNA表达谱,但尚未确定哪组miRNA可以构成强有力的诊断测试,以预测BE向EAC的进展。方法:使用miRNA测序分析鉴定与BE向EAC进展有关的miRNA。通过定量逆转录聚合酶链反应(qRT-PCR)进一步验证了两组BE患者,这些BE患者在至少随访5年后已发展为或未发展为腺癌。结果:在与BE相关的致癌过程中,通过miRNA测序分析鉴定出23个miRNA。使用独立组织样品进行的qRT-PCR分析证实了其中的19种(miR-let-7c,7、146a,149、153、192、192 *,194、194 *,196a,196b,200a,203、205, 215、424、625、625 *和944)。但是,与未进展为EAC的患者相比,只有miR-192、194、196a和196b在BE样品中显示出显着更高的水平。结论:这些发现表明,在化生组织活检中少量miRNA的表达模式可以确定BE患者发生EAC的高风险。因此,它具有控制和治疗这种恶性肿瘤的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号